Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin

Nicole Casadevall, J Nataf, B Viron et al. · New England Journal of Medicine · 2002 · 1.2K citations

Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Timothy J. Littlewood, Emilio Bajetta, J.W.R. Nortier et al. · Journal of Clinical Oncology · 2001 · 976 citations

Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.

Nicholas J. Vogelzang, William Breitbart, David Cella et al. · PubMed · 1997 · 771 citations

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

George D. Demetri, Mark G. Kris, James L. Wade et al. · Journal of Clinical Oncology · 1998 · 756 citations

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

John A. Glaspy, Ronald Bukowski, Douglas Steinberg et al. · Journal of Clinical Oncology · 1997 · 705 citations